A Phase 2/3 interventional study of Placebo and EXPAREL 67 mg in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 3rd largest by enrollment, is one of 6 that started in 2012, is one of 5 in phase 2/3, and was the 2nd registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Tianjin First Central Hospital · Sites in China
Ages 18–80
Texas Scottish Rite Hospital for Children · Sites in United States
Ages 13–21
Boston Children's Hospital · Sites in United States
Ages 10–17
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 16 · Phase 4 52
First in 2012; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 297 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 93 interventional studies. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one has the largest enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2012, is the only one in phase 2/3, and was the 15th registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
8 of the studies testing Liposomal Bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT06271265Pacira Pharmaceuticals, IncStudy to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | 2027-01 |
| NCT07689162Washington University School of MedicineLiposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be tested in Part 2.
Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic effect of single injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo (preservative-free normal saline).
This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA) under general or spinal anesthesia. Note: Bupivacaine cannot be used as the spinal anesthetic.
Part 1 During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to receive a single dose injection femoral nerve block with either one of three doses of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance. Preservative-free normal saline will be added to the 67 mg and 133 mg doses of study drug to achieve a volume of 20 mL.
Part 2 In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately 90 liposome bupivacaine subjects and 90 placebo subjects) will receive a single dose injection femoral nerve block with the selected dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of .
If of , must have a documented negative pregnancy test within 24 hours before surgery.
Use of any of the following medications within the times specified before surgery:
long-acting opioid medication, NSAIDs, aspirin (except for low-dose aspirin used for cardioprotection) or acetaminophen within 3 days, or and any opioid medication within 24 hours.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
Drug: EXPAREL 67 mg
10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
Drug: EXPAREL 133 mg
20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
Drug: EXPAREL 266 mg
20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
Drug: Placebo
20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
Drug: EXPAREL 266 mg
20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
Drug: Placebo
Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
Also known as: Preservative-free normal saline.
5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
Also known as: Bupivacaine liposome injectable suspension 67 mg/5 mL
10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
Also known as: Bupivacaine liposome injectable suspension 133 mg/10 mL
20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
Also known as: Bupivacaine liposome injectable suspension 266 mg/20 mL
Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours
AUC of NRS-R pain intensity scores through 72 hours. Pain intensity scores were measured on an 11-point NRS (0=no pain and 10=worst possible pain)
Time frame: 0-72 hours
Total Postsurgical Opioid Consumption Through 72 Hours
Total postsurgical opioid consumption of opioid rescue pain medication (converted to IV morphine equivalents) through 72 hours
Time frame: 0-72 hours
Time to First Opioid Rescue Through 72 Hours
Time to first opioid rescue medication consumed through 72 hours
Time frame: 0-72 hours
Participants were recruited between September 24, 2012 and December 20, 2013 at 23 sites in the US
| Milestone | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| Started | 25 | 26 | 25 | 25 | 0 | 0 |
| Completed | 21 | 22 | 22 | 20 | 0 | 0 |
| Not completed | 4 | 4 | 3 | 5 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 | 1 | 0 | 0 |
| Withdrew: Surgery cancelled | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive study drug | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Early termination; met exclusion criteria | 0 | 2 | 1 | 0 | 0 | 0 |
| Milestone | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 99 | 97 |
| Completed | 0 | 0 | 0 | 0 | 82 | 82 |
| Not completed | 0 | 0 | 0 | 0 | 17 | 15 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 3 |
| Withdrew: Surgery cancelled | 0 | 0 | 0 | 0 | 4 | 2 |
| Withdrew: Did not receive study drug | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Met exclusion criterion | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by investigator decision | 0 | 0 | 0 | 0 | 1 | 2 |
AUC of NRS-R pain intensity scores through 72 hours. Pain intensity scores were measured on an 11-point NRS (0=no pain and 10=worst possible pain)
| score on a scale * hr | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours | 533.4 ± 33.15 | 427.2 ± 31.73 | 436.2 ± 31.79 | 530.5 ± 31.73 | 418.9 ± 16.86 | 515.5 ± 16.95 |
Total postsurgical opioid consumption of opioid rescue pain medication (converted to IV morphine equivalents) through 72 hours
| mg morphine equivalents | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| Total Postsurgical Opioid Consumption Through 72 Hours | 126.69 ± 75.972 | 100.35 ± 53.177 | 105.96 ± 53.402 | 124.78 ± 58.743 | 93.19 ± 58.133 | 122.08 ± 70.312 |
Time to first opioid rescue medication consumed through 72 hours
| hours | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| Time to First Opioid Rescue Through 72 Hours | 0.49 (0.300 to 0.650) | 0.37 (0.283 to 0.700) | 1.29 (0.367 to 2.350) | 0.41 (0.300 to 0.550) | 0.44 (0.400 to 0.533) | 0.43 (0.367 to 0.567) |
Collected over From screening through postsurgical day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| (Part 1) EXPAREL 67 mg | 0/22 (0%) | 4/22 (18.2%) | 19/22 (86.4%) |
| (Part 1) EXPAREL 133 mg | 0/24 (0%) | 2/24 (8.3%) | 20/24 (83.3%) |
| (Part 1) EXPAREL 266 mg | 0/24 (0%) | 1/24 (4.2%) | 21/24 (87.5%) |
| (Part 1) Placebo | 0/24 (0%) | 3/24 (12.5%) | 21/24 (87.5%) |
| (Part 2) EXPAREL 266 mg | 0/92 (0%) | 8/92 (8.7%) | 82/92 (89.1%) |
| (Part 2) Placebo | 0/92 (0%) | 9/92 (9.8%) | 83/92 (90.2%) |
| Event | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 2/22 | 0/24 | 1/24 | 0/24 | 1/92 | 2/92 |
| CellulitisInfections and infestations | 1/22 | 0/24 | 0/24 | 0/24 | 0/92 | 0/92 |
| Wound DehiscenceInjury, poisoning and procedural complications | 1/22 | 0/24 | 0/24 | 1/24 | 0/92 | 0/92 |
| Liver function test abnormalInvestigations | 1/22 | 0/24 | 0/24 | 0/24 | 0/92 | 0/92 |
| Acute Prerenal FailureRenal and urinary disorders | 1/22 | 0/24 | 0/24 | 0/24 | 0/92 | 0/92 |
| Deep Vein ThrombosisVascular disorders | 1/22 | 0/24 | 0/24 | 0/24 | 0/92 | 0/92 |
| PyrexiaGeneral disorders | 0/22 | 0/24 | 0/24 | 0/24 | 4/92 | 1/92 |
| Device Related InfectionInfections and infestations | 0/22 | 0/24 | 0/24 | 1/24 | 0/92 | 0/92 |
| Wound InfectionInfections and infestations | 0/22 | 0/24 | 0/24 | 1/24 | 0/92 | 1/92 |
| Wound DecompositionInjury, poisoning and procedural complications | 0/22 | 0/24 | 0/24 | 1/24 | 0/92 | 0/92 |
| Event | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 8/22 | 14/24 | 13/24 | 9/24 | 49/92 | 61/92 |
| VomitingGastrointestinal disorders | 1/22 | 0/24 | 1/24 | 2/24 | 26/92 | 38/92 |
| PyrexiaGeneral disorders | 8/22 | 7/24 | 8/24 | 3/24 | 28/92 | 24/92 |
| PruritisSkin and subcutaneous tissue disorders | 1/22 | 2/24 | 2/24 | 2/24 | 33/92 | 31/92 |
| ConstipationGastrointestinal disorders | 3/22 | 2/24 | 6/24 | 1/24 | 32/92 | 32/92 |
| DizzinessNervous system disorders | 3/22 | 3/24 | 4/24 | 6/24 | 15/92 | 19/92 |
| AnaemiaBlood and lymphatic system disorders | 4/22 | 1/24 | 4/24 | 2/24 | 8/92 | 5/92 |
| InsomniaPsychiatric disorders | 1/22 | 2/24 | 2/24 | 4/24 | 5/92 | 11/92 |
| Urinary RetentionRenal and urinary disorders | 1/22 | 0/24 | 0/24 | 0/24 | 12/92 | 6/92 |
| HeadacheNervous system disorders | 1/22 | 3/24 | 2/24 | 1/24 | 5/92 | 4/92 |
Safety population included all participants who received study drug, with analysis by actual treatment received.
| Age, Continuous(years) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 68.5 ± 8.41 | 65.7 ± 7.30 | 66.4 ± 8.94 | 66.1 ± 12.17 | 66.4 ± 10.35 | 63.6 ± 8.76 | 65.0 ± 9.67 |
| Sex: Female, Male(Participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 8 | 16 | 14 | 14 | 52 | 57 | 161 |
| Male | 14 | 8 | 10 | 10 | 40 | 35 | 117 |
| Ethnicity (NIH/OMB)(Participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 | 3 | 8 | 9 | 24 |
| Not Hispanic or Latino | 21 | 23 | 22 | 21 | 84 | 83 | 254 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 | 0 | 2 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 2 | 4 | 15 | 14 | 38 |
| White | 20 | 22 | 21 | 20 | 75 | 76 | 234 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 22 | 24 | 24 | 24 | 92 | 92 | 278 |
| American Society of Anesthesiologists (ASA) classification(Participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1 | 0 | 7 | 3 | 11 |
| 2 | 11 | 16 | 13 | 15 | 38 | 49 | 142 |
| 3 | 11 | 8 | 10 | 9 | 47 | 40 | 125 |
| >/= 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Type of Anesthesia(Participants) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| General | 15 | 17 | 12 | 21 | 62 | 56 | 183 |
| Spinal | 6 | 7 | 12 | 3 | 28 | 35 | 91 |
| Other | 1 | 0 | 0 | 0 | 2 | 0 | 3 |
| Duration of Surgery(minutes) | (Part 1) EXPAREL 67 mg | (Part 1) EXPAREL 133 mg | (Part 1) EXPAREL 266 mg | (Part 1) Placebo | (Part 2) EXPAREL 266 mg | (Part 2) Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 85.8 ± 25.53 | 88.5 ± 27.96 | 96.0 ± 37.94 | 85.0 ± 35.53 | 94.1 ± 34.43 | 94.9 ± 37.54 | 94.5 ± 35.9 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2020, 7 years after primary completion. A results delay was requested in Mar 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine